InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Greene Barry E, Chairman & CEO. Officer active across 2 companies, notably Sage Therapeutics, Inc.. In total, 8 reports have been published. Split: 5 buys · 0 sell. Total volume traded: €3m. Activity tracked since 16 June 2021. The latest transaction was disclosed on 10 April 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations8 total
19,964 shares0Common StockSEC:0001562180-25-003112:0
50,400 shares0Common StockSEC:0001562180-24-006090:0
14,500 shares@ US$34.484316.4% of flowCommon StockSEC:0001562180-22-007667:0
Ideal exit: 7 Aug 2023 (T+270)
7,576 shares@ US$1.485100.0% of flowCommon StockSEC:0001209191-22-045718:0
23,640 shares@ US$43.149533.8% of flowCommon StockSEC:0001562180-21-005226:0
Ideal exit: 2 May 2022 (T+270)
23,640 shares@ US$43.149528.3% of flowCommon StockSEC:0001562180-21-005226
Ideal exit: 2 May 2022 (T+270)
8,800 shares@ US$56.321313.6% of flowCommon StockSEC:0001562180-21-004342
Ideal exit: 13 Mar 2022 (T+270)
8,800 shares@ US$56.321316.2% of flowCommon StockSEC:0001562180-21-004342:0
Ideal exit: 13 Mar 2022 (T+270)
8 of 8 declarations
About Greene Barry E
Barry E. Greene is the President and CEO of Sage Therapeutics, Inc. He leads the company with a focus on innovation in healthcare. Under his leadership, Sage Therapeutics is committed to developing innovative treatments for patients.
